Everest Medicines Limited (HKG: 1952)
Hong Kong
· Delayed Price · Currency is HKD 35.15
+0.35 (1.01%)
Nov 15, 2024, 4:08 PM HKT
Everest Medicines Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Net Income | - | -844.46 | -247.28 | -1,009 | -5,658 | -214.51 | Upgrade
|
| Depreciation & Amortization | - | 63.62 | 40.23 | 30.76 | 20.4 | 10 | Upgrade
|
| Other Amortization | - | 13.15 | 2.55 | 0.37 | 10.05 | - | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 1.43 | -1,320 | - | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 51.97 | 16.49 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | -0.85 | 21.75 | - | - | - | Upgrade
|
| Stock-Based Compensation | - | 73.42 | 206.5 | 224.98 | 117.27 | 14.95 | Upgrade
|
| Other Operating Activities | - | -46.19 | 153.15 | -11.67 | 4,963 | 16.05 | Upgrade
|
| Change in Accounts Receivable | - | -44.64 | -5.17 | -0.05 | - | - | Upgrade
|
| Change in Inventory | - | -7.31 | -11.19 | -0.45 | - | - | Upgrade
|
| Change in Accounts Payable | - | -116.55 | 70.43 | 73.97 | 86.68 | 51.25 | Upgrade
|
| Change in Other Net Operating Assets | - | 87.22 | -83.63 | -39.13 | -10.77 | 33.62 | Upgrade
|
| Operating Cash Flow | - | -769.19 | -1,156 | -729.94 | -471.9 | -88.66 | Upgrade
|
| Capital Expenditures | - | -117.34 | -355.92 | -109.95 | -8.6 | -7.08 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0.06 | 0.31 | - | - | - | Upgrade
|
| Cash Acquisitions | - | - | - | - | - | 98.44 | Upgrade
|
| Sale (Purchase) of Intangibles | - | 1,432 | 488.17 | -865.87 | -511.33 | -86.19 | Upgrade
|
| Investment in Securities | - | -568.77 | -1,161 | - | - | - | Upgrade
|
| Other Investing Activities | - | 6.57 | - | - | - | -52.53 | Upgrade
|
| Investing Cash Flow | - | 752.5 | -1,028 | -975.82 | -519.93 | -47.37 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | - | 70.3 | Upgrade
|
| Long-Term Debt Issued | - | 451.46 | - | - | 348.59 | - | Upgrade
|
| Total Debt Issued | - | 451.46 | - | - | 348.59 | 70.3 | Upgrade
|
| Long-Term Debt Repaid | - | -463.2 | -30.59 | -23.66 | -19.46 | -8.3 | Upgrade
|
| Net Debt Issued (Repaid) | - | -11.74 | -30.59 | -23.66 | 329.13 | 62 | Upgrade
|
| Issuance of Common Stock | - | 29.79 | 5.28 | 5.86 | 3,387 | - | Upgrade
|
| Repurchase of Common Stock | - | - | - | -58.71 | - | - | Upgrade
|
| Other Financing Activities | - | -7.95 | - | - | -10.05 | - | Upgrade
|
| Financing Cash Flow | - | 10.1 | -25.31 | -76.51 | 5,638 | 62 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | 38.87 | 59.83 | -58.81 | -270.99 | -3.42 | Upgrade
|
| Net Cash Flow | - | 32.28 | -2,149 | -1,841 | 4,375 | -77.44 | Upgrade
|
| Free Cash Flow | - | -886.53 | -1,512 | -839.89 | -480.5 | -95.74 | Upgrade
|
| Free Cash Flow Margin | - | -703.97% | -11817.36% | -1555344.44% | - | - | Upgrade
|
| Free Cash Flow Per Share | - | -2.83 | -5.08 | -2.86 | -5.63 | -18.32 | Upgrade
|
| Cash Interest Paid | - | 7.95 | - | - | - | - | Upgrade
|
| Levered Free Cash Flow | - | 2,356 | -2,031 | -1,339 | -857.73 | -132.49 | Upgrade
|
| Unlevered Free Cash Flow | - | 2,371 | -2,028 | -1,336 | -836.57 | -131.24 | Upgrade
|
| Change in Net Working Capital | - | -1,438 | 1,531 | -39.44 | 34.66 | -61.17 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.